Skip to main content
Cipla Ltd. logo

Cipla Ltd. — Investor Relations & Filings

Ticker · CIPLA ISIN · INE059A01026 LEI · 335800KMJJYEDDK82Q34 BSE.NS Manufacturing
Open in API
Filings indexed 2,634 across all filing types
Latest filing 2022-08-16 Board/Management Inform…
Country IN India
Listing BSE.NS CIPLA

About Cipla Ltd.

https://www.cipla.com/

Cipla Ltd. is a global pharmaceutical company focused on the development, manufacturing, and marketing of a wide range of generic and branded medicines. The company maintains a diverse portfolio of over 1,500 products across various therapeutic areas, including respiratory, anti-retroviral, urology, cardiology, anti-infective, and central nervous system treatments. It is recognized for its leadership in respiratory care and its historical role in making HIV/AIDS treatment affordable through the introduction of low-cost antiretroviral drugs. Operating with a strong emphasis on research and development, the firm utilizes advanced technology to produce complex generics and drug delivery systems. Its global footprint spans multiple continents, serving healthcare providers and patients in numerous international markets through a robust supply chain and manufacturing infrastructure.

Recent filings

Filing Released Lang Actions
Appointment
Board/Management Information Classification · 95% confidence The document is a formal notification addressed to stock exchanges and regulatory bodies about the appointment of a new Global Chief Financial Officer and Key Managerial Personnel. It includes details about the appointment, the outgoing interim CFO, and a brief profile of the new appointee. There are no financial statements, earnings data, or detailed management discussion. The content is focused on management changes at the board or senior management level. Therefore, this document fits the category of Board/Management Information (MANG). The document length and detail support this classification with high confidence.
2022-08-16 English
Cipla Limited has informed the Exchange about relieving Mr. Dinesh Jain from the additional responsibility of interim Chief Financial Officer of the company w.e.f. 16-Aug-2022. Mr. Dinesh ....
Board/Management Information Classification · 95% confidence The document is a formal notification addressed to stock exchanges and regulatory bodies about the appointment of a new Global Chief Financial Officer and Key Managerial Personnel. It includes details about the appointment, the outgoing interim CFO, and a brief profile of the new appointee. There are no financial statements, earnings data, or detailed management discussion of financial results. The document is an announcement of a change in senior management, specifically the CFO position, which fits the category of Board/Management Information (MANG). The document length (8853 characters) supports it being a detailed announcement rather than a brief notice or a full report. Therefore, the appropriate classification is MANG with high confidence.
2022-08-16 English
Resignation
Board/Management Information Classification · 100% confidence The document text contains information about the appointment and relieving of key managerial personnel, specifically the appointment of Mr. Ashish Adukia as Global Chief Financial Officer and the relieving of Mr. Dinesh Jain as interim CFO. It includes details such as dates of appointment, terms, and brief profiles. There is no financial data, report, or regulatory filing mentioned. The content clearly relates to changes in senior management positions.
2022-08-16 English
Cipla (EU) Limited, ("Cipla EU"), wholly owned subsidiary of the Company in UK, has agreed to acquire an additional 19.16% stake in Cipla Maroc SA, joint venture and subsidiary of Cipla EU in Morocco.
Capital/Financing Update Classification · 95% confidence The document is an official notification addressed to stock exchanges and regulatory bodies regarding a corporate acquisition transaction. It references compliance with SEBI Listing Regulations, specifically Regulation 30 and Schedule III, which pertain to disclosure of material events and information by listed companies. The content details the acquisition of an additional stake in a subsidiary joint venture, including specifics about the target entity, transaction nature, consideration, and regulatory approvals. There are no financial statements or comprehensive financial performance data presented, nor is this a report or presentation. The document is a formal announcement of a capital transaction affecting the company's holdings. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and detail support a high confidence classification.
2022-08-04 English
Acquisition
Capital/Financing Update Classification · 95% confidence The document is an official notification addressed to stock exchanges and regulatory bodies regarding an acquisition transaction by Cipla EU Limited, a subsidiary of Cipla Limited. It references compliance with SEBI Listing Regulations, specifically Regulation 30 and Schedule III, which pertain to disclosure of material events and information. The content details the acquisition of an additional stake in a joint venture, including specifics about the target entity, transaction nature, consideration, and regulatory approvals. There are no financial statements or comprehensive financial performance data presented, nor is this a transcript, report, or presentation. The document is a formal announcement of a capital transaction (acquisition of shares) and related disclosures under listing regulations. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length and detail support a confident classification.
2022-08-04 English
Pursuant to Regulation 39(3) and other applicable regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that Registrar and ....
Regulatory Filings Classification · 85% confidence The document contains a table listing shareholder details such as folio number, name, certificate number, number of shares, and distinctive share numbers. There is no indication of financial data, management discussion, voting results, or regulatory announcements. The content resembles a shareholder register or shareholding details, but it is not a notification of major shareholding changes or director dealings. Given the lack of context and the nature of the data, this document does not fit into any specific detailed category and is best classified as a general Regulatory Filing (RNS). The document is very short (333 characters), so it is not a full report but a brief data listing.
2022-08-04 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.